Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
797.2
1 812.45
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Glenmark Pharmaceuticals Ltd
Income from Continuing Operations
Glenmark Pharmaceuticals Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
|
Income from Continuing Operations
-₹9.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Income from Continuing Operations
₹54.3B
|
CAGR 3-Years
40%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Income from Continuing Operations
₹44.9B
|
CAGR 3-Years
20%
|
CAGR 5-Years
22%
|
CAGR 10-Years
14%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Income from Continuing Operations
₹111.4B
|
CAGR 3-Years
21%
|
CAGR 5-Years
18%
|
CAGR 10-Years
5%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Income from Continuing Operations
₹18B
|
CAGR 3-Years
12%
|
CAGR 5-Years
27%
|
CAGR 10-Years
8%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Income from Continuing Operations
₹19.4B
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Glenmark Pharmaceuticals Ltd
Glance View
Glenmark Pharmaceuticals Ltd., founded in 1977 by Gracias Saldanha, has crafted its journey from a single-product company to a noteworthy player in the global pharmaceutical landscape. Headquartered in Mumbai, India, its growth has been driven by a formidable strategy of focusing on both generics and novel drug discovery. In the fiercely competitive world of pharmaceuticals, Glenmark carved its niche by building a diverse product portfolio that spans across dermatology, respiratory, and oncology segments, among others. The company’s nuanced understanding of therapeutic areas and its pursuit of complex generics have empowered it to not only tap into established markets but also venture into emerging ones across 80 countries. This international strategy, combined with robust research and development infrastructure, underscores how Glenmark leverages scientific innovation to ensure steady revenue streams. At the heart of Glenmark's operations lies its commitment to research-driven growth. The company allocates significant resources to its R&D initiatives, manifesting in state-of-the-art facilities across India, Switzerland, and the U.S. Through these centers, Glenmark focuses on the development of differentiated generic medicines and the discovery of innovative therapeutic molecules. The synergy between its generic and innovative drug segments enables Glenmark to sustain profitability by capitalizing on patent expiries while simultaneously pioneering novel drug therapies. This dual approach not only helps the company secure a competitive position in the pharmaceutical market but also fuels its earnings through a balanced mix of volume-driven sales and premium pricing of differentiated products.
See Also
What is Glenmark Pharmaceuticals Ltd's Income from Continuing Operations?
Income from Continuing Operations
-9.9B
INR
Based on the financial report for Sep 30, 2024, Glenmark Pharmaceuticals Ltd's Income from Continuing Operations amounts to -9.9B INR.
You don't have any saved screeners yet
